MYGN Q2 2022 Earnings — Myriad Genetics, Inc. Revenue & Financial Results | Market Cap Arena

MYGNMyriad Genetics, Inc.

$487M

Q2 2022 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$179M-5.3% YoY

Gross Profit

$130M72.3% margin

Operating Income

-$18M-9.9% margin

Net Income

-$14M-7.9% margin

EPS (Diluted)

$-0.18

QoQ Revenue Growth

+8.7%

Cash Flow

Operating Cash Flow

-$50M

Free Cash Flow

-$56M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$263M

Stockholders' Equity

$947M

Cash & Equivalents

$105M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$179M	$189M	-5.3%
Gross Profit	$130M	$136M	-4.5%
Operating Income	-$18M	-$21M	+14.4%
Net Income	-$14M	-$5M	-200.0%

Geographic Segments

UNITED STATES

$22M64%

Non-US

$12M36%